Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures

Cancer Research

Volumn 73, Issue 2, 2013, Pages 978-989

  Ju, Xiaoming ^a   Ertel, Adam ^a   Casimiro, Mathew C ^a   Yu, Zuoren ^a   Meng, Hui ^a   McCue, Peter A ^b   Walters, Rhonda ^a   Fortina, Paolo ^a   Lisanti, Michael P ^a,b   Pestell, Richard G ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; GENE EXPRESSION; GENETIC TRANSDUCTION; HA RAS GENE; HUMAN; KAPLAN MEIER METHOD; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; V SRC GENE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENES, MYC; GENES, RAS; GENES, SRC; LUNG NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; ONCOGENES; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; TRANSCRIPTOME;

EID: 84872563780     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2133     Document Type: Article

References (47)

1. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23: 8253-61.
2. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18: 11-22.
3. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1: 203-9.
4. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101: 811-6.
5. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412: 822-6.
6. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002;62: 4499-506.
7. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113: 913-23.
8. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4: 223-38.
9. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91: 13-25.
10. Creighton CJ. Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors. PLoS ONE 2008;3:e1816.
11. Paronetto MP, Farini D, Sammarco I, Maturo G, Vespasiani G, Geremia R, et al. Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer. Am J Pathol 2004;164: 1243-51.
12. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nature Rev Cancer 2007;7: 256-69.
13. Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011;8: 551-61.
14. Bull JH, Ellison G, Patel A, Muir G, Walker M, Underwood M, et al. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 2001;84: 1512-9.
15. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56: 917-30.
16. Hensley PJ, Kyprianou N.Modeling prostate cancer in mice: limitations and opportunities. J Androl 2011;33: 133-44.
17. Ilio KY, Nemeth JA, Lang S, Lee C. The primary culture of rat prostate basal cells. J Androl 1998;19: 718-24.
18. Li Z, Wang C, Jiao X, Lu Y, Fu M, Quong AA, et al. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol 2006;26: 4240-56.
19. Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, Katiyar S, et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A 2009;106: 19035-9.
20. Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, et al. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res 2009;69: 7793-802.
21. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom- Sternberg S, et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 2011;21: 47-55.
22. Anderson PD, McKissic SA, Logan M, Roh M, Franco OE, Wang J, et al. Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest 2012;122: 1907-19.
23. Markert EK, Mizuno H, Vazquez A, Levine AJ. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A 2011;108: 21276-81.
24. Huang ES, Black EP, Dressman H, West M, Nevins Jr. Gene expression phenotypes of oncogenic signaling pathways. Cell Cycle 2003;2: 415-17.
25. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, et al. SMAD4- dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470: 269-73.
26. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152: 2037-42.
27. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98: 1128-33.
28. Akimoto S, Furuya Y, Akakura K, Shimazaki J, Ito H. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase. Int J Urol 1997;4: 572-5.
29. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61: 5974-8.
30. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: stem cell biology. Urology 2003;62: 11-20.
31. Roy-Burman P,WuH, PowellWC, Hagenkord J,CohenMB.Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocrine-related Cancer 2004;11: 225-54.
32. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 2004;64: 8867-75.
33. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002;347: 1593-603.
34. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004;6: 171-83.
35. Ruley HE. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 1983;304: 602-6.
36. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001;15: 50-65.
37. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400: 464-8.
38. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983;304: 596-602.
39. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 2002;22: 2111-23.
40. Bianchi-Frias D, Pritchard C, Mecham BH, Coleman IM, Nelson PS. Genetic background influences murine prostate gene expression: implications for cancer phenotypes. Genome Biol 2007;8:R117.
41. Fabozzi SJ, Schellhammer PF, el-Mahdi AM. Pulmonary metastases from prostate cancer. Cancer 1995;75: 2706-9.
42. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-Myc oncogene amplification and chromosomal anomloies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57: 524-31.
43. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, et al. Clinical significance of alterations of chromosome 8 in highgrade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999;91: 1574-80.
44. Mori S, Chang JT, Andrechek ER, Potti A, Nevins Jr. Utilization of genomic signatures to identify phenotype-specific drugs. PLoS ONE 2009;4:e6772.
45. Casimiro M, Rodriguez O, Pootrakul L, Aventian M, Lushina N, Cromelin C, et al. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res 2007;67: 4364-72.
46. Gioeli D, Kraus S, Weber MJ. Signal transduction by the Ras-MAP kinase pathway in prostate cancer progression. In:Pestell RG, Nevalainen MT, editors. Prostate cancer: signaling networks, genetics, and new treatment strategies. Totowa, NJ: Humana Press; 2008. p. 223-56.
47. Scherl A, Li JF, Cardiff RD, Schreiber-Agus N. Prostatic intraepithelial neoplasia and intestinal metaplasia in prostates of probasin-RAS transgenic mice. Prostate 2004;59: 448-59.